Drug Database · Clinicians

Pyrazinamide

Brands (13) Zynaphar, Pyracox, Pyragen…Show all

Antimycobacterial US FDA class
Antituberculosis agent; Anti-tuberculosis PH FDA category

Rx · Prescription drug21 PH productsPNF-listedVAT-exempt (some products)
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 262d8829-728c-48db-b89b-88d13b87e684, version date March 2, 2026 (Pyrazinamide · ANI Pharmaceuticals, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS & USAGE Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
US FDA label
Full indications and usage US FDA label

INDICATIONS & USAGE Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4) (Patients with drug-resistant disease should be treated with regimens individualized to their situation.

Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of current recommendations of CDC. It is possible these patients may require a longer course of treatment.) It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis.

Pyrazinamide should only be used in conjunction with other effective antituberculous agents. *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations. 4

Contraindications

CONTRAINDICATIONS Pyrazinamide is contraindicated in persons: with severe hepatic damage. who have shown hypersensitivity to it. with acute gout.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE & ADMINISTRATION Pyrazinamide should always be administered with other effective antituberculous drugs. It is administered for the initial 2 months of a 6-month or longer treatment regimen for drug-susceptible patients. Patients who are known or suspected to have drug-resistant disease should be treated with regimens individualized to their situation.

Pyrazinamide frequently will be an important component of such therapy. Patients with concomitant HIV infection may require longer courses of therapy. Physicians treating such patients should be alert to any revised recommendations from CDC for this group of patients. Usual dose: Pyrazinamide is administered orally, 15 to 30 mg/kg once daily.

Older regimens employed 3 to 4 divided doses daily, but most current recommendations are for once a day. Three grams per day should not be exceeded. The CDC recommendations do not exceed 2 g per day when given as a daily regimen (see table). Alternatively, a twice weekly dosing regimen (50 to 70 mg/kg twice weekly based on lean body weight) has been developed to promote patient compliance with a regimen on an outpatient basis.

In studies evaluating the twice weekly regimen, doses of pyrazinamide in excess of 3 g twice weekly have been administered. This exceeds the recommended maximum 3 g/daily dose. However, an increased incidence of adverse reactions has not been reported. The table is taken from the CDC-American Thoracic Society joint recommendations: 4 Recommended Drugs for the Initial Treatment of Tuberculosis in Children and Adults Drug Daily Dose* Maximal Daily Dose in Children and Adults Twice Weekly Dose Children Adults Children Adults Isoniazid 10 to 20 mg/kg PO or IM 5 mg/kg PO or IM 300 mg 20 to 40 mg/kg Max. 900 mg 15 mg/kg Max. 900 mg Rifampin 10 to 20 mg/kg PO 10 mg/kg PO 600 mg 10 to 20 mg/kg Max. 600 mg 10 mg/kg Max. 600 mg Pyrazinamide 15 to 30 mg/kg PO 15 to 30 mg/kg PO 2 g 50 to 70 mg/kg 50 to 70 mg/kg Streptomycin 20 to 40 mg/kg IM 15 mg/kg** IM 1 g** 25 to 30 mg/kg IM 25 to 30 mg/kg IM Ethambutol 15 to 25 mg/kg PO 15 to 25 mg/kg PO 2.5 g 50 mg/kg 50 mg/kg Definition of abbreviations: PO = perorally; IM = intramuscularly. * Doses based on weight should be adjusted as weight changes. **In persons older than 60 yrs of age the daily dose of streptomycin should be limited to 10 mg/kg with a maximal dose of 750 mg.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

PEDIATRIC USE Pyrazinamide regimens employed in adults are probably equally effective in pediatric patients. 4, 10, 11 Pyrazinamide appears to be well tolerated in pediatric patients.

Dosing: Older adult

Geriatric use (US label) US FDA label

GERIATRIC USE Clinical studies of pyrazinamide did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic or renal function, and of concomitant disease or other drug therapy.

It does not appear that patients with impaired renal function require a reduction in dose. It may be prudent to select doses at the low end of the dosing range, however. 13

Dosage forms

Philippines

  • Suspension: 250 mg/5 mL, 500 mg per 5 mL, 500 mg/5 mL
  • Tablet: 500 mg
  • Oral suspension: 250 mg/5 mL, 500 mg/5 mL

Registered products in the Philippines

21 products registered with the Food and Drug Administration (FDA) Philippines list Pyrazinamide as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: yrazinamide (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products21
Philippine FDA-registered products for Pyrazinamide
Package insert
NonePyrazinamide
250 mg/5 mL Oral SuspensionAmber boston round bottle x 60 mL (Box of 1's); Amber boston round bottle x 120 mL (Box of 1's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DRP-9123
Sep 4, 2030
NonePyrazinamide
250 mg/5 mL SuspensionAmber bottle x 60 mL
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DR-XY38648
Oct 18, 2030
NonePyrazinamide
250 mg/5 mL SuspensionBoston Round Amber Bottle x 60 mL (Box of 1's); Boston Round Amber Bottle x 120 mL (Box of 1's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
—
DRP-5757
Jan 17, 2028
NonePyrazinamide
250 mg/5 mL SuspensionBoston Round Amber Bottle x 120mL (Box of 1's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
TGP Pharma Inc.
DRP-5757-02
Jan 17, 2028
NonePyrazinamide
500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
J.M. TOLMANN LABORATORIES INC.Philippines
—
DRP-1403
Mar 19, 2029
NonePyrazinamide
500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
J.M. Tolmann Laboratories Inc.Philippines
Firstmed Theraconcept Inc.
DRP-1403-01
Mar 19, 2029
PyracoxPyrazinamide
500 mg TabletAlu-PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Huazhong Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-15923
Oct 1, 2029
PyragenPyrazinamide
250 mg/5 mL SuspensionBoston Round Amber Bottle x 120 mL (Box of 1's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
Eba Generisch Trading Inc.
DRP-16547-01
Apr 29, 2030
PyraminPyrazinamide
250 mg/5 mL SuspensionBoston Round Amber Bottle x 60 mL and 120 mL (Box of 1's)
RxVAT-exempt
Drugmaker's Laboratories, INc.Philippines
Terramedic, Inc.
DRP-5757-01
Jan 17, 2028
Pyrazisaph-500Pyrazinamide
500 mg/5 mL Oral SuspensionRound Amber Glass Bottle with white ROPP Aluminum Cap x 60 mL and 120 mL (Box of 1's)
RxVAT-exempt
Bueno Salud Care India Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-13060
Oct 14, 2031
PyrazuerPyrazinamide
500 mg TabletAlu/PVC Blister Pack x 10’s Box of 100’s
RxVAT-exempt
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DR-XY27982
Oct 24, 2027
PyzatherPyrazinamide
250 mg/5 mL Suspension60 mL and 120 mL Amber Bottle (Box of 1's)
RxVAT-exempt
San Marino Laboratories CorporationPhilippines
—
DRP-5771
Jul 25, 2028
RapnamidePyrazinamide
250 mg / 5 mL SuspensionBoston Round Amber Bottle x 120 mL (Box of 1's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-16547-02
Apr 29, 2030
Saphyrazin-500Pyrazinamide
500 mg/ 5 mL Oral SuspensionPET round amber bottle x 60 mL and 120 mL (Box of 1's)
RxVAT-exempt
Azine Healthcare Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-12267
Jul 7, 2027
UnbrandedPyrazinamide
500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 28's (Box of 672's)
RxVAT-exempt
Macleods Pharmaceuticals LimitedIndia
Importer: Macleods Pharmaceuticals Philippines, Inc.
DRP-6854
Oct 7, 2031
ZcurePyrazinamide
250 mg/5 mL SuspensionBoston Round Glass Amber Bottle x 120 mL (Box of 1's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Natrapharm, Inc.
DR-XY27677
Jan 14, 2029
Zcure FortePyrazinamide
500 mg/ 5 mL SuspensionBoston Round Glass Amber Bottle x 120 mL (Box of 1's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Natrapharm, Inc.
DR-XY35466
Feb 17, 2029
ZinaplexPyrazinamide
500 mg per 5 mL SuspensionAmber bottle x 120 mL
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY28007
Jan 7, 2028
ZynamaxyrazinamideVariant spelling
250 mg/5 mL SuspensionBoston Round Amber Bottle x 120 mL (Box of 1's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-16547
Apr 29, 2030
ZynapharPyrazinamide
250 mg/5 mL Oral SuspensionAmber Bottle x 60 mL & 120 mL (Box of 1's)
RxVAT-exempt
J.M. Tolmann Laboratories Inc.Philippines
—
DRP-2050
Oct 29, 2030
ZYNAPHARPyrazinamide
500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
J.M. TOLMANN LABORATORIES INC.Philippines
TGP PHARMA INC.
DRP-1403-02
Mar 19, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Patients started on pyrazinamide should have baseline serum uric acid and liver function determinations. Those patients with preexisting liver disease or those at increased risk for drug related hepatitis (e.g., alcohol abusers) should be followed closely. Pyrazinamide should be discontinued and not be resumed if signs of hepatocellular damage or hyperuricemia accompanied by an acute gouty arthritis appear.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS General Fever, porphyria and dysuria have rarely been reported. Gout (see PRECAUTIONS). Gastrointestinal The principal adverse effect is a hepatic reaction (see WARNINGS). Hepatotoxicity appears to be dose related, and may appear at any time during therapy. GI disturbances including nausea, vomiting and anorexia have also been reported.

Hematologic and Lymphatic Thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. Adverse effects on blood clotting mechanisms have also been rarely reported. Other Mild arthralgia and myalgia have been reported frequently.

Hypersensitivity reactions including rashes, urticaria, and pruritus have been reported. Fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely.

Pregnancy considerations

Pregnancy (US label) US FDA label

PREGNANCY Teratogenic Effects – Pregnancy Category C Animal reproduction studies have not been conducted with pyrazinamide. It is also not known whether pyrazinamide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Pyrazinamide should be given to a pregnant woman only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

NURSING MOTHERS Pyrazinamide has been found in small amounts in breast milk. Therefore, it is advised that pyrazinamide be used with caution in nursing mothers taking into account the risk-benefit of this therapy. 9

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The CSF concentration is approximately equal to concurrent steady-state plasma concentrations in patients with inflamed meninges. 1 Pyrazinamide is approximately 10% bound to plasma proteins. 2 The half-life (t 1/2 ) of pyrazinamide is 9 to 10 hours in patients with normal renal and hepatic function.

The plasma half-life may be prolonged in patients with impaired renal or hepatic function.

Pyrazinoic acid is hydroxylated to the main excretory product, 5-hydroxypyrazinoic acid. 3 Approximately 70% of an oral dose is excreted in urine, mainly by glomerular filtration within 24 hours. 3 Pyrazinamide may be bacteriostatic or bactericidal against Mycobacterium tuberculosis depending on the concentration of the drug attained at the site of infection.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Pyrazinamide is well absorbed from the GI tract and attains peak plasma concentrations within 2 hours. Plasma concentrations generally range from 30 to 50 mcg/mL with doses of 20 to 25 mg/kg. It is widely distributed in body tissues and fluids including the liver, lungs and cerebrospinal fluid (CSF).

The CSF concentration is approximately equal to concurrent steady-state plasma concentrations in patients with inflamed meninges. 1 Pyrazinamide is approximately 10% bound to plasma proteins. 2 The half-life (t 1/2) of pyrazinamide is 9 to 10 hours in patients with normal renal and hepatic function. The plasma half-life may be prolonged in patients with impaired renal or hepatic function.

Pyrazinamide is hydrolyzed in the liver to its major active metabolite, pyrazinoic acid. Pyrazinoic acid is hydroxylated to the main excretory product, 5-hydroxypyrazinoic acid. 3 Approximately 70% of an oral dose is excreted in urine, mainly by glomerular filtration within 24 hours. 3 Pyrazinamide may be bacteriostatic or bactericidal against Mycobacterium tuberculosis depending on the concentration of the drug attained at the site of infection.

The mechanism of action is unknown. In vitro and in vivo the drug is active only at a slightly acidic pH.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Pyrazinamide 500 mg Tablet₱1.85–₱3.49Reference ₱1.85per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Pyrazinamide
PNF listingOral: 500 mg tablet
PNF listingOral: 250 mg/5 mL and 500 mg/ 5mL suspension, 120 mL
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Pyrazinamide · ANI Pharmaceuticals, Inc. [US FDA-approved label, version 2, March 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=262d8829-728c-48db-b89b-88d13b87e684
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .